5-HTP- Educational Materials

5-Hydroxytryptophan (5-HTP) is a naturally occurring amino acid that the body uses to produce serotonin, a key neurotransmitter involved in mood, sleep and other functions [1]. It is widely marketed in the United States as a sleep aid, but it is also used as a complementary and alternative therapy (CAM) to treat depression and to reduce appetite.

Unlike many other molecules, 5-HTP easily crosses the blood-brain barrier and raises serotonin levels in the brain, potentially producing an antidepressant-like effect [1]. However, its rapid breakdown in the body (with a half-life of about 2 hours) once made it less practical as a drug. Recently, a slow-release version of 5-HTP was developed. This new formulation lasts longer in the body and shows promise in treating depression, especially when combined with SSRI drugs. In addition to helping with depression, 5-HTP has shown benefits in several other conditions, such as insomnia, chronic headaches, fibromyalgia and obesity [1].

5-HTP in the treatment of depression

5-Hydroxytryptophan (5-HTP), a key precursor of serotonin, continues to attract the attention of researchers and health professionals for its potential role in treating symptoms of depression. Various scientific studies, including clinical trials and animal studies, have shown positive results with 5-HTP in the treatment of depression. In a controlled clinical trial, PD patients who received 5-HTP showed significant improvement in depressive symptoms, as measured by standardized rating scales such as the Hamilton Depression Rating Scale (HDRS) [2]. This antidepressant effect was observed at a modest daily dose of 50 mg and was sustained over a four-week treatment period. These benefits were observed even in the complex neurological and pharmacological context of Parkinson's disease. This suggests that 5-HTP may help regulate mood in people struggling with multiple underlying challenges. The pronounced effect of 5-HTP on depression indicates its value as a potential complementary treatment option.

Although 5-HTP has been less frequently studied compared to other antidepressants, research indicates that it may be effective in alleviating symptoms of depression. In a research study, seventy patients with a first episode of depression were randomized to receive 5-HTP or fluoxetine for eight weeks [3]. Both groups were regularly checked using the Hamilton Depression Rating Scale (HAM-D) at the beginning of the study and again at the second, fourth and eighth weeks. In the end, the results showed that 5-HTP led to a noticeable improvement in depressive symptoms, starting after just two weeks of treatment. This improvement was similar to that observed with fluoxetine. At the end of the study, about three-quarters of patients taking 5-HTP and four-fifths of patients taking fluoxetine showed a positive response. Importantly, 5-HTP worked in people with all levels of depression, not just those with milder symptoms. 5-HTP was found to be both safe and effective, working as well as fluoxetine. This finding is important because it suggests that 5-HTP may be a helpful treatment option for people who cannot tolerate traditional SSRIs or do not get improvement. This study supports the concept that 5-HTP can be an effective antidepressant and can alleviate symptoms at levels similar to well-known drugs.

It is worth noting that early studies conducted in Europe in the 1970s and early 1980s showed that 5-HTP, in doses of 200 to 3,000 mg per day, reduced depressive symptoms in about 60% patients in one study - no improvement was seen in the placebo group [4]. Other studies have shown that 5-HTP worked almost as well as some antidepressants, such as clomipramine and imipramine, and was helpful in more than half of the patients tested in open trials.

Similarly, studies conducted in Japan in the 1970s showed significant improvements in a large number of patients taking 5-HTP in doses of 50 to 300 mg daily, often with benefits appearing in less than two weeks - faster than with most traditional antidepressants. In a few cases, results were mixed. A 1985 British study found that 5-HTP did not help patients who did not respond to other antidepressants. However, later studies continued to show that 5-HTP can work just as well as some standard antidepressants for many people. For example, a 1991 Swiss study comparing 5-HTP (100 mg three times a day) and fluvoxamine (50 mg three times a day) showed that both therapies were equally effective, with improvement beginning as early as the second week. While many of these studies focused on people with major depression, some studies also suggest that L-tryptophan, in doses of about 3 grams a day, can help people with mild to moderate depression, providing relief similar to tricyclic antidepressants, but with fewer side effects.

What's more, a detailed meta-analysis showed that taking 5-HTP supplements orally can significantly help reduce depressive symptoms [5]. In most of the studies reviewed, many patients achieved remission, and when all scores were combined, there was significant overall improvement. On average, people's scores on the Hamilton Depression Rating Scale fell by 12.7 points. To put this into perspective, a drop of 12 points can move someone from severe depression into the normal mood range. Even when the analysis focused only on higher-quality studies, the positive effect remained large. A key detail is that the newer studies included taking 5-HTP for longer periods of time (42 and 56 days) compared to the older studies (some as short as 5 days). Longer treatment seemed to lead to better outcomes, although the researchers did not formally analyze treatment duration as a factor. Given that most antidepressants don't take effect until several weeks later, it makes sense that taking 5-HTP longer may be important. Despite some shortcomings in existing studies, the meta-analysis suggests that 5-HTP may have a strong positive effect on depression, and future, more rigorous studies may provide even clearer guidance on how best to use it.

In another small, open-label study, 15 women with major depressive disorder (MDD) were given 5 grams of creatine monohydrate daily plus 100 mg of 5-HTP twice daily for 8 weeks, followed by a 4-week follow-up period [6]. It's worth noting that these participants were already taking SSRIs or SNRIs, but were still experiencing significant symptoms (scores of 16 or higher on the 17-item Hamilton Depression Rating Scale, or HAM-D). The results were encouraging, as the mean HAM-D score dropped from 18.9 before treatment to 7.5 after, a reduction of 60%. Equally important, there were no serious treatment-related side effects. These results suggest that the simultaneous use of creatine and 5-HTP may provide a helpful shot in the arm for women whose depression has not fully responded to traditional antidepressants.

In addition, an open study tested L-Deprenil with L-5-HTP and benzerazide in 14 patients with unipolar or bipolar depression [7]. Of the 14 patients who received the combination, 10 showed a good response. In another double-blind, controlled study, researchers compared three groups of patients with affective disorders: one group received L-Deprenil plus L-5-HTP and benzerazide, a second group received only L-5-HTP and benzerazide, and a third group received a placebo. Patients taking L-Deprenil together with L-5-HTP showed significantly better mood improvement than those taking placebo. Patients taking only L-5-HTP, however, did not show a similar advantage over placebo. The results suggest a potential benefit of 5-HTP in the fight against depression.

Moreover, in a double-blind controlled study, researchers compared the effects of nialamide plus L-5-HTP with nialamide plus placebo in 30 hospitalized patients with endogenous depression [8]. The study showed that patients who received the combination of nialamide and L-5-HTP experienced a more pronounced and faster recovery compared to those treated with nialamide alone. This accelerated improvement was observed in key symptoms of depression, suggesting that L-5-HTP may enhance the therapeutic effects of nialamide by directly targeting serotonin production. Importantly, the study highlighted the potential of combining traditional antidepressants with serotonin precursors, such as L-5-HTP, to achieve better outcomes in people with major depressive disorder. The findings point to the value of adjunctive therapies for improving recovery rates in hospitalized depressed patients.

In a study focusing on elderly patients (mean age 68) struggling with depression, a combination treatment containing dihydroergocristin (3 mg) and lev-5-hydroxytryptophan (100 mg) was compared with placebo for 60 days [9]. During the study, the researchers used psychological tests and depression rating scales to measure changes in mood and mental function. At the end of the study, the group receiving the combination of dihydroergocristin and 5-HTP showed a marked improvement in depressive symptoms and overall mental performance. In contrast, those given a placebo experienced no significant changes. Importantly, the combination treatment was also well tolerated, with no significant side effects. These results suggest that adding 5-HTP to a treatment regimen may have a positive impact on depression in older adults, offering both mood improvement and cognitive benefits.

Many people suffering from treatment-resistant depression (TRD) find that standard antidepressants do not provide enough relief. Studies show that adding 5-HTP to an existing antidepressant can increase serotonin levels more effectively than serotonin transporter (SERT) inhibitors alone [10]. This may be particularly helpful for people who do not respond well to traditional treatments. However, regular 5-HTP does not stay in the body for long periods of time, making it difficult to use consistently. Researchers believe that a slow-release version of 5-HTP could solve this problem by providing a steady supply over time [10]. Early animal studies support this idea, and if confirmed in humans, a slow-release 5-HTP supplement could be a valuable new option for people who are not helped by current treatments for depression.

Moreover, in an open study, 25 depressed patients were treated with L-5-hydroxytryptophan (L-5-HTP), either alone or together with a peripheral decarboxylase inhibitor [11]. Overall, L-5-HTP worked as well as traditional antidepressants. There was no clear difference in efficacy between the two methods of administration. The best results occurred in patients who were anxious and agitated, and in those with acute endogenous depression. Importantly, improvement was often noticed quickly - within 3 to 5 days. It is worth noting that gastrointestinal side effects were dose-related and occurred more frequently in patients taking L-5-HTP without the inhibitor. Meanwhile, psychological side effects, such as sudden anxiety, were more frequently reported among patients who took L-5-HTP with a peripheral decarboxylase inhibitor.

Additionally, in a double-blind study, 26 hospitalized patients with depression were divided into two groups [12]. Both groups received a low dose of chlorimipramine (50 mg/day), but one group (group A) also received 5-HTP (300 mg/day), while the other (group B) received a placebo. During the 28-day study, two patients in the placebo group dropped out of the study. All patients were assessed weekly using the Hamilton Rating Scale for Depression (HRSD), the Zung Depression Self-Assessment Inventory (ZDSI) and the Clinical General Impression (CGI) scale. Statistical comparisons - using both the Student's t-test and the Mann-Whitney test - showed that the addition of 5-HTP to chlorimipramine led to a greater reduction in HRSD scores, reaching significance at the 0.05 level. This positive trend was observed for both reactive and endogenous depression, with patients in Group A overall showing both quantitative and qualitative improvements compared to Group B. These results suggest that combining 5-HTP with an antidepressant such as chlorimipramine may improve therapeutic outcomes in patients with depression.

Moreover, the researchers sought to enhance the antidepressant effect of L-5-hydroxytryptophan (L-5-HTP) by combining it with a low dose of the antidepressant drug clomipramine [13]. For the first two weeks, patients received 200-400 mg of L-5-HTP along with a peripheral decarboxylase inhibitor (MK 486) to minimize side effects. In the following two weeks, 50 mg of clomipramine was added to the treatment. Two patients discontinued treatment due to gastrointestinal problems, but four of the remaining five showed improvement after taking L-5-HTP alone. Adding clomipramine further improved symptoms in two of these patients, indicating that even a low dose of clomipramine can enhance the antidepressant effect of L-5-HTP. These results suggest that L-5-HTP may benefit patients refractory to other treatments, and that its efficacy can be enhanced when combined with a low dose of a traditional antidepressant.

Moreover, a young man with severe, treatment-resistant depression and multiple suicide attempts was diagnosed with a deficiency in the pterin biosynthesis pathway, resulting in low levels of tetrahydrobiopterin (BH4), neopterin and key neurotransmitter metabolites [14]. This deficiency impaired the synthesis of dopamine and serotonin. Replacing BH4 with sapropterin improved suicidal symptoms, but did not fully address depression. Adding 5-hydroxytryptophan (5-HTP) along with carbidopa, which provided more serotonin production in the brain, significantly improved it. Starting with a low dose and gradually increasing it to 400 mg twice a day, 5-HTP provided mood stability, better sleep and lasting relief from severe depression. Over time, as BH4 levels normalized and 5-HTP therapy continued, the patient's mood further improved and he regained daily functioning. This case underscores the potential of 5-HTP in treating complex, difficult-to-treat depression, especially when standard therapies have failed, by effectively increasing serotonin levels in the brain.

Another study examining the antidepressant potential of 5-hydroxytryptophan (5-HTP) highlighted its efficacy, especially when combined with tryptophan, compared to other treatments such as nomifensine [15]. The combination of tryptophan and 5-HTP showed significant improvements in depressive symptoms, particularly in reducing depressive inhibition, agitation, anxiety and somatic complaints. This synergistic effect was consistent with various assessment tools, including the Hamilton Depression Scale and self-report measures such as the Zung and v. Zerssen, highlighting the higher efficacy of combination therapy.

Moreover, the treatment showed a favorable safety profile, with no reported significant gastrointestinal or physiological side effects, a common problem in antidepressant therapies [15]. The integration of behavioral therapy, including cognitive restructuring and other structured interventions, likely complemented the pharmacological effects of 5-HTP, enhancing its therapeutic efficacy. These findings underscore the potential of 5-HTP, especially in combination with tryptophan, as a viable and effective treatment strategy for depression.

Moreover, in a clinical trial, eighteen depressed patients were treated with oral L-5-HTP (150-300 mg/day) [16]. The results showed significant improvement in most participants: 2 improved significantly, 8 improved significantly, 3 improved minimally, and 5 remained unchanged. The antidepressant effect of L-5-HTP was often rapid. Interestingly, those responding to L-5-HTP showed a greater increase in serotonin levels after one week compared to non-responders, suggesting a link between treatment efficacy and baseline serotonin metabolism. Depressed patients showed a slower and smaller increase in serotonin levels after a single oral dose of 3 mg/kg L-5-HTP, compared to mania or healthy subjects. This indicates that some depressed individuals may have metabolic abnormalities in the conversion of L-5-HTP to serotonin, which may contribute to their symptoms. These findings suggest that L-5-HTP may be particularly effective in patients with low levels of serotonin in the brain, although metabolic inefficiencies in converting L-5-HTP to serotonin may limit its effectiveness in some individuals.

Another study examined the rapid antidepressant potential of DL-5-hydroxytryptophan (5-HTP) used together with monoamine oxidase (MAO) inhibitors [17]. Typically, antidepressants require two to three weeks to show initial effects, which is attributed to the time needed for "tissue saturation." The researchers hypothesized that increasing the levels of certain amino acids or their derivatives could accelerate this response. Testing intravenous 5-HTP (doses of 25-50 mg) in combination with various MAO inhibitors (including Actomol, Parnate and Marplan), they observed marked improvements in many patients within 24 hours. Among the 50 patients with outpatient depression, 90% those with "classic" or "pure" depression experienced significant relief, while the response rate was lower for patients with more complex conditions such as schizoaffective depression or depression associated with cerebral arteriosclerosis. For patients who relapsed, repeat injections of 5-HTP consistently restored improvement, in contrast to placebo (saline). The rapid response to 5-HTP, often within 12 hours, shows its potential as an effective and fast-acting antidepressant, especially in combination with MAO inhibitors.

A thorough review of clinical trials of 5-hydroxytryptophan for the treatment of depression conducted in 2006 revealed mixed but somewhat promising results [24]. Researchers analyzed 27 studies involving a total of 990 patients, using a wide range of study designs, treatment durations and doses. Eleven of the studies were double-blinded and placebo-controlled, the most reliable type of design. In 7 of them, 5-HTP was superior to placebo, although many of these studies were too small and only 5 of them reached statistical significance [24]. Several studies compared 5-HTP with other antidepressants. In two of these comparisons, 5-HTP worked about as well as the drug tested. However, in other studies involving patients who did not respond to standard treatment, 5-HTP did not fare as well, especially when compared to tranylcypromine [24]. Another study tested 5-HTP both with and without a peripheral decarboxylase inhibitor (which helps keep more 5-HTP available to the brain) and found limited improvement in both groups [24].

Despite these mixed results, several studies have shown that 5-HTP can significantly reduce depressive symptoms, especially when combined with other antidepressants [24]. In one study, combining 5-HTP with the antidepressant nialamide resulted in greater improvement than using nialamide alone. Another showed that adding 5-HTP to clomipramine helped patients improve more than clomipramine alone. In addition, three monotherapy studies showed that 5-HTP alone was better than placebo, although the sample size was small. This evidence suggests that 5-HTP may have some antidepressant potential.

5-Hydroxytryptophan (5-HTP) for other mental health conditions

5-Hydroxytryptophan (5-HTP) has been extensively studied for its potential to alleviate symptoms of depression, but its benefits may extend to other psychiatric conditions as well. Studies suggest that the compound may offer therapeutic benefits for a range of disorders, including anxiety, panic attacks, obsessive-compulsive disorder (OCD) and even sleep disorders.

A 12-week randomized, double-blind study evaluated the efficacy of 5-hydroxytryptophan (5-HTP) as an adjunctive treatment for moderate to severe obsessive-compulsive disorder (OCD) [18]. Sixty patients with diagnosed OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score above 21 were assigned to a group receiving fluoxetine plus 5-HTP (100 mg twice daily) or fluoxetine plus placebo. Fluoxetine was given at a dose of 20 mg/day for the first 4 weeks and increased to 60 mg/day for the remainder of the study. The results showed that the addition of 5-HTP significantly improved outcomes compared to fluoxetine alone.

At 12 weeks, the 5-HTP group showed a greater reduction in total Y-BOCS scores, as well as obsessions and compulsions subscale scores, with significant time × treatment interactions (P < 0.001, P = 0.001 and P = 0.002, respectively). In addition, the 5-HTP group had higher rates of partial and complete treatment responses (P = 0.032 and P = 0.001, respectively). These findings support the potential of 5-HTP as an effective adjunctive therapy in patients with moderate to severe OCD, enhancing the effects of standard fluoxetine treatment and providing a promising serotonergic pathway for treating OCD symptoms.

Moreover, w Another study involving ten outpatients diagnosed with anxiety disorders based on DSM-III criteria examined the therapeutic effects of L-5-hydroxytryptophan (L-5-HTP) in combination with carbidopa [19]. The treatment led to a significant reduction in anxiety symptoms, as consistently demonstrated on three different anxiety rating scales. This significant improvement underscores the potential role of serotonin (5-HT) systems in modulating anxiety, as L-5-HTP is a direct precursor of serotonin and can increase its levels in the brain.

The combination with carbidopa is particularly important because it prevents the peripheral breakdown of L-5-HTP, ensuring that more of it reaches the brain, where it can be converted to serotonin. This mechanism enhances the therapeutic efficacy of L-5-HTP while minimizing potential side effects associated with peripheral serotonin activity. These findings suggest that L-5-HTP, especially when combined with carbidopa, may serve as a promising treatment option for anxiety disorders. Its ability to directly affect the serotonergic pathway offers an alternative or complementary approach to traditional treatments for anxiety, such as selective serotonin reuptake inhibitors (SSRIs).

In addition, the study examined the effects of L-5-hydroxytryptophan (5-HTP) on panic reactions in people with paroxysmal anxiety syndrome. Previous studies have indicated that reduced serotonin availability increases susceptibility to panic, while higher levels of serotonin can help alleviate panic reactions. In this study, 24 patients with panic disorder and 24 healthy volunteers participated in a 35% CO₂ panic challenge after receiving 200 mg of 5-HTP or placebo [20]. The results showed that 5-HTP significantly reduced panic reactions in patients with panic disorder, including less subjective anxiety, fewer panic symptoms and fewer panic attacks compared to placebo. However, 5-HTP had no significant effect in healthy volunteers. These findings indicate that 5-HTP may reduce panic reactions in people with panic disorder, highlighting the role of serotonin in coping with the condition and positioning 5-HTP as a promising treatment option.

5-HTP and the microbiota-gut-brain axis

The gut and the brain are closely linked, influencing each other in many ways. 5-HTP plays a key role in this connection, supporting serotonin production and improving gut health. This compound, known as the microbiota-gut-brain axis, has shown potential in treating depression and mood disorders.

In an interesting study [21], researchers looked at how 5-HTP affects the gut microbiome - the community of bacteria living in the digestive system - which is believed to play a role in depression through the so-called "gut-brain microbiota axis." They discovered that when mice exhibited depression-like symptoms, the balance of their gut bacteria was altered. Treating these mice with 5-HTP helped restore healthier patterns in their gut microbiome. After taking 5-HTP, the mice's gut bacterial communities became more diverse and returned to a balance closer to that of healthy mice.

In addition, depression-induced changes in certain brain-associated growth factors (called brain-derived neurotrophic factors, or BDNFs) and short-chain fatty acids (important molecules produced by gut bacteria) were partially reversed by 5-HTP treatment. These findings suggest that 5-HTP may help treat depression not only by increasing serotonin levels in the brain, but also by promoting a healthier gut environment. This gives us new clues about how 5-HTP works and may help us use it more effectively in treating depression and other related conditions.

What's more, research on Morinda officinalis oligosaccharides (MOO) - an approved oral medication for depression in China - shows that the compound enhances the gut's ability to produce and store 5-HTP from tryptophan [22]. Although MOO itself is not well absorbed, it indirectly improves serotonin-related processes in the gut microbiota. It does so by increasing tryptophan hydroxylase, the enzyme that converts tryptophan into 5-HTP. At the same time, it decreases the activity of 5-hydroxytryptophan decarboxylase, which would otherwise convert 5-HTP into serotonin in the gut. By allowing 5-HTP to accumulate, MOO ensures that more 5-HTP enters the bloodstream, passes through the blood-brain barrier and ultimately increases serotonin levels in the brain, thereby alleviating symptoms of depression. These results show for the first time that altering gut microbial metabolism can increase 5-HTP levels, which in turn increases serotonin levels in the brain. These findings suggest that approaches to increase 5-HTP - either through direct supplementation or by influencing gut microbiota activity - could potentially serve as a new strategy for treating depression.

Similarly, another study found that certain strains of lactic acid bacteria (LAB) can help alleviate symptoms of depression in mice [23]. Mice were subjected to mild, unpredictable stress for five weeks while being given LAB supplements. Two strains, Bifidobacterium longum subsp. infantis E41 i Bifidobacterium breve M2CF22M7, stood out. In cellular experiments, the strains increased expression of the Tph1 enzyme and boosted production of 5-hydroxytryptophan (5-HTP), a key precursor of serotonin. When stressed mice were given these bacteria, they showed fewer symptoms of depression in several behavioral tests. The mice also had higher levels of serotonin and brain-derived neurotrophic factor in their brains - both important for mood regulation. In addition, strain M2CF22M7 helped lower the stress hormone corticosterone, while E41 increased beneficial gut compounds such as butyrate, which have been linked to improvements in depression-related indicators.

Further analysis showed that both E41 and M2CF22M7 improved the balance of gut microbes altered by chronic stress. These bacteria also helped restore normal metabolic and genetic activity in the host. These findings suggest that introducing these specific gut bacteria may improve mood, at least in part by increasing 5-HTP and promoting a healthier microbiome.

How does 5-HTP work in the body?

Once taken, 5-HTP is rapidly absorbed into the bloodstream and crosses the blood-brain barrier without the need for special transport mechanisms. In the brain, it is converted to serotonin by an enzyme called aromatic L-amino acid decarboxylase and vitamin B6. This direct pathway makes 5-HTP more effective than tryptophan, a related compound that requires additional steps to become serotonin. By increasing serotonin levels, 5-HTP improves communication between brain cells, which can help reduce symptoms of depression and anxiety. It also interacts with serotonin receptors, promoting feelings of calm and emotional stability. In addition, 5-HTP affects the gut-brain connection, increasing the production of serotonin in the gut, which is believed to play a role in mood regulation. Combining 5-HTP with certain medications, such as SSRIs or carbidopa, can increase its effectiveness while minimizing side effects such as nausea. Because 5-HTP directly addresses serotonin imbalances often found in depression, it offers a fast-acting and targeted way to improve mood.

Overview of 5-HTP

Over the years, a wealth of evidence has suggested that 5-HTP is a promising mood-enhancing supplement, particularly for treating symptoms of depression. Unlike tryptophan, which requires multiple metabolic steps to become serotonin, 5-HTP is a direct precursor to serotonin. This allows it to easily cross the blood-brain barrier and potentially increase serotonin levels more reliably. Studies have shown that 5-HTP can produce antidepressant effects comparable to commonly prescribed drugs such as SSRIs, sometimes in just a few weeks - faster than many traditional treatments. The findings span a variety of populations, from patients with mild to severe depression to those suffering from co-occurring neurological conditions such as Parkinson's disease.

In addition to its effects on mood, 5-HTP has shown benefits in several other areas related to mental and physical well-being. Studies indicate that it can help alleviate insomnia, chronic headaches, fibromyalgia, anxiety and even obesity. Importantly, emerging research also points to the importance of the gut-brain axis. By potentially restoring a healthier balance in the gut microbiome, 5-HTP may enhance mood regulation from within, adding a new dimension to understanding and treating depression and related disorders. These gut findings suggest that 5-HTP's benefits may not just be limited to serotonin production, but also to supporting the body's natural microbial environment, thereby influencing mood through multiple pathways.

From a safety standpoint, moderate doses of 5-HTP (typically 50 to 300 mg daily) are generally well tolerated, although some individuals may experience mild gastrointestinal side effects. These issues are often dose-dependent and can often be managed by adjusting intake. Although many studies indicate good tolerability, caution is advised when using 5-HTP in combination with other serotonergic substances, such as SSRIs, due to the risk of excessive serotonin levels. Nevertheless, its mild side-effect profile compared to many standard antidepressants makes it a potentially attractive option, especially for those who have not fully responded to or cannot tolerate conventional therapies.

Despite these encouraging findings, it is important to be aware of the limitations of the current evidence. Some studies included small samples or lacked rigorous methodology, and more large-scale, long-term studies are needed to fully establish the role of 5-HTP in clinical practice. In addition, the best dosing strategies, treatment duration and protocols for combining with standard medications remain topics of ongoing research. Nevertheless, the weight of existing research suggests that 5-HTP may soon gain a more central place in the depression treatment landscape, offering hope as both a complementary and alternative option to traditional antidepressants. As the scientific community continues to explore, 5-HTP represents a promising approach to mood regulation that may ultimately benefit a wide range of patients.

How is 5-HTP produced in the body?

The body produces 5-HTP from the amino acid tryptophan using an enzyme called tryptophan hydroxylase. The conversion of tryptophan into 5-HTP is the slowest (or "rate-limiting") step in the production of serotonin. Once 5-HTP is formed, it is quickly converted to serotonin with the help of another enzyme and vitamin B6. Since serotonin itself cannot easily pass from the bloodstream to the brain, the use of 5-HTP can help increase serotonin levels in the brain.

5-HTP metabolism?

5-HTP easily crosses the blood-brain barrier (unlike serotonin itself) and is then converted to serotonin in the brain. Any extra 5-HTP is likely to be broken down and removed from the body, especially if vitamin B6 is present. Sometimes doctors combine 5-HTP with drugs that slow its breakdown outside the brain (such as carbidopa or benserazide). This can increase the effectiveness of 5-HTP over a longer period of time, potentially improving its effects on mood and other functions.

Dietary sources of 5-HTP

Although 5-HTP itself is not found in significant amounts in food, it is closely related to tryptophan, an amino acid found in all protein-containing foods. The body uses tryptophan to produce 5-HTP and then serotonin.

How much 5-HTP per day?

The commonly recommended dose of 5-HTP for most purposes is. 100-300 mg per day, usually taken in divided doses (such as 50 mg twice a day). It is important not to exceed the dose suggested by your doctor, as too much 5-HTP can lead to side effects or serotonin syndrome, a potentially dangerous condition caused by excessive serotonin levels. It is always recommended to start with a lower dose and consult your doctor for guidance.

Side effects of 5-HTP

Despite its potential health benefits, 5-HTP is not without risks. Common side effects include gastrointestinal problems, headaches and sleep disturbances. More serious risks, such as serotonin syndrome, occur when it is combined with other serotonergic agents.

Disclaimer

This article was written for educational purposes and is intended to raise awareness of the substance being discussed. It is important to note that the substance discussed is a substance, not a specific product. The information contained in the text is based on available scientific research and is not intended to serve as medical advice or promote self-medication. The reader should consult any health and treatment decisions with a qualified health professional.

References

1. Maffei, M.E., 2020. 5-Hydroxytryptophan (5-HTP): Natural occurrence, analysis, biosynthesis, biotechnology, physiology and toxicology. International journal of molecular sciences, 22(1), s.181. https://www.com/1422-0067/22/1/181
2. Meloni, M., Puligheddu, M., Carta, M., Cannas, A., Figorilli, M., and Defazio, G., 2020. Efficacy and safety of 5-hydroxytryptophan in the treatment of depression and apathy in Parkinson's disease: preliminary study results. European Journal of Neurology, 27(5), pp.779-786. https://onlinelibrary.com/doi/full/10.1111/ene.14179
3. Jangid, P., Malik, P., Singh, P., and Sharma, M., 2013. A comparative study of the efficacy of l-5-hydroxytryptophan and fluoxetine in patients with first episode depression. Asian journal of psychiatry, 6(1), pp.29-34. https://onlinelibrary.com/doi/full/10.1111/ene.14179
4. Meyers, S., 2000. the use of neurotransmitter precursors in the treatment of depression. Alternative Medicine Review, 5(1), pp.64-71. https://jeffreydachmd.com/wp-content/uploads/2013/08/Neurotransmitter-Precursors-for-Depression-5HTP-Stephen-Meyers-Alt-Med-Rev-2000.pdf
5. Javelle, Florian; Lampit, Amit; Bloch, Wilhelm; Häussermann, Peter; Johnson, Sheri L; Zimmer, Philipp . (2019). Effects of 5-hydroxytryptophan on different types of depression: a systematic review and meta-analysis. Nutrition Reviews, (), nuz039-. doi:10.1093/nutrit/nuz039 https://pismin.com/10.1093/nutrit/nuz039
6. Kious BM, Sabic H, Sung YH, Kondo DG, Renshaw P. An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women. J Clin Psychopharmacol. 2017;37(5):578-583. doi:10.1097/JCP.0000000000000754 https://pubmed.nlm.nih.gov/28787372/
7. Mendlewicz J, Youdim MB. Antidepressant enhancement of 5-hydroxytryptophan by L-deprenil in affective disorder. J Affect Disord. 1980;2(2):137-146. doi:10.1016/0165-0327(80)90013-0 https://pubmed.ncbi.nlm.nih.gov/6448885/
8. Aliño JJ, Gutierrez JL, Iglesias ML. 5-Hydroxytryptophan (5-HTP) and MAOI (nialamide) in the treatment of depression. A double-blind controlled study. Int Pharmacopsychiatry. 1976;11(1):8-15. doi:10.1159/000468207 https://pubmed.ncbi.nlm.nih.gov/770365/
9. Rousseau JJ. Effects of the combination of lev-5-hydroxytryptophan and dihydroergocristine on depression and neuropsychiatric performance: a double-blind placebo-controlled clinical trial in elderly patients. Clin Ther. 1987;9(3):267-272. https://pubmed.ncbi.nlm.nih.gov/3111702/
10. Jacobsen JPR, Krystal AD, Krishnan KRR, Caron MG. Slow-release 5-Hydroxytryptophan in the treatment of treatment-resistant depression: Clinical and preclinical rationale. Trends Pharmacol Sci. 2016;37(11):933-944. doi:10.1016/j.tips.2016.09.001 https://pubmed.ncbi.nlm.nih.gov/27692695/
11. Zmilacher K, Battegay R, Gastpar M. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology. 1988;20(1):28-35. doi:10.1159/000118469 https://pubmed.ncbi.nlm.nih.gov/3265988/
12. Nardini M, De Stefano R, Iannuccelli M, Borghesi R, Battistini N. Treatment of depression with L-5-hydroxytryptophan in combination with chlorimipramine, a double-blind study. Int J Clin Pharmacol Res. 1983;3(4):239-250. https://pubmed.ncbi.nlm.nih.gov/6381336/.
13. Herman M. Praag; Willem Burg; Erik R. H. Bos; Louise C. W. Dols. (1974). 5-Hydroxytryptophan in combination with clomipramine in "therapy-resistant" depression. , 38(3), 267-269. doi:10.1007/bf00421379 https://pismin.com/10.1007/bf00421379
14. Pan L, McKain BW, Madan-Khetarpal S, Mcguire M, Diler RS, Perel JM, Vockley J, Brent DA. GTP-cyclohydrolase deficiency responding to sapropterin and 5-HTP supplementation: alleviation of treatment-resistant depression and suicidal behaviour. BMJ Case Rep. 2011 Jun 9;2011:bcr0320113927. doi: 10.1136/bcr.03.2011.3927. Erratum in: BMJ Case Rep. 2011;2011:bcr0320113927corr1. doi: 10.1136/bcr.03.2011.3927.corr1. PMID: 22691588; PMCID: PMC3116226. https://pmc.nlm.nih.gov/articles/PMC3116226/
15. Quadbeck; E. Lehmann; J. Tegeler. (1984). Comparison of the Antidepressant Action of Tryptophan, Tryptophan/5-Hydroxytryptophan Combination and Nomifensine. , (), -. doi:10.1159/000118063 https://pismin.com/10.1159/000118063
16. Kaneko M, Kumashiro H, Takahashi Y, Hoshino Y. L-5HTP treatment and serum 5-HT levels after L-5-HTP loading in depressed patients. Neuropsychobiology. 1979;5(4):232-240. doi:10.1159/000117687 https://pubmed.ncbi.nlm.nih.gov/312470/
17. CLINE, NATHAN S.; SACKS, WILLIAM . (1963). RELIEF OF DEPRESSION IN ONE DAY WITH M.A.O. INHIBITOR AND INTRAVENOUS 5-HTP. American Journal of Psychiatry, 120(3), 274-275. doi:10.1176/ajp.120.3.274 https://pismin.com/10.1176/ajp.120.3.274
18. Yousefzadeh F, Sahebolzamani E, Sadri A, et al. 5-Hydroxytryptophan as adjunctive therapy for the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2020;35(5):254-262. doi:10.1097/YIC.0000000000000321 https://pubmed.nlm.nih.gov/32541380/
19. Kahn RS, Westenberg HG. L-5-hydroxytryptophan in the treatment of anxiety disorders. J Affect Disord. 1985;8(2):197-200. doi:10.1016/0165-0327(85)90046-1 https://pubmed.ncbi.nlm.nih.gov/3157732/
20. Schruers K, van Diest R, Overbeek T, Griez E. Acute administration of L-5-hydroxytryptophan inhibits carbon dioxide-induced panic in patients with panic disorder. Psychiatry Res. 2002;113(3):237-243. doi:10.1016/s0165-1781(02)00262-7 https://pubmed.ncbi.nlm.nih.gov/12559480/
21. Wu, L., Ran, L., Wu, Y., Liang, M., Zeng, J., Ke, F., Wang, F., Yang, J., Lao, X., Liu, L., and Wang, Q., 2022. Oral administration of 5-hydroxytryptophan restores gut microbiota dysbiosis in a mouse model of depression. Frontiers in Microbiology, 13, s. 864571. https://www.org/journals/microbiology/articles/10.3389/fmicb.2022.864571/full
22. Zhang ZW, Gao CS, Zhang H, et al. Oligosaccharides Morinda officinalis increase serotonin levels in the brain and relieve depression via Promoting 5-hydroxytryptophan production in the gut microbiota. Acta Pharm Sin B. 2022; 12 (8): 3298-3312. doi: 10.1016/j.apsb.2022.02.032 https://pubmed.ncbi.nlm.nih.gov/35967282/
23. Tian P, Wang G, Zhao J, Zhang H, Chen W. Bifidobacterium with a role in regulating 5-hydroxytryptophan synthesis alleviates symptoms of depression and associated microbiota dysbiosis. J Nutr Biochem. 2019;66:43-51. doi:10.1016/j.jnutbio.2019.01.007 https://pubmed.ncbi.nlm.nih.gov/30743155/
24. Erick H. Turner; Jennifer M. Loftis; Aaron D. Blackwell. (2006). Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. , 109(3), 325-338. doi:10.1016/j.pharmthera.2005.06 https://pismin.com/10.1016/j.pharmthera.2005.06.004.